Emergent Biosolutions, Inc. (EBS): Price and Financial Metrics


Emergent Biosolutions, Inc. (EBS)

Today's Latest Price: $89.97 USD

0.80 (-0.88%)

Updated Oct 30 7:00pm

Add EBS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

EBS Stock Summary

  • Emergent BioSolutions Inc's market capitalization of $4,761,652,263 is ahead of 77.4% of US-listed equities.
  • Over the past twelve months, EBS has reported earnings growth of -660,600%, putting it ahead of just 0% of US stocks in our set.
  • As for revenue growth, note that EBS's revenue has grown 43.4% over the past 12 months; that beats the revenue growth of 88.54% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Emergent BioSolutions Inc are PPSI, RAD, SYNA, QGEN, and RCM.
  • EBS's SEC filings can be seen here. And to visit Emergent BioSolutions Inc's official web site, go to www.emergentbiosolutions.com.

EBS Stock Price Chart Interactive Chart >

Price chart for EBS

EBS Price/Volume Stats

Current price $89.97 52-week high $137.61
Prev. close $90.77 52-week low $46.37
Day low $88.45 Volume 405,794
Day high $91.03 Avg. volume 648,991
50-day MA $104.29 Dividend yield N/A
200-day MA $83.79 Market Cap 4.76B

Emergent Biosolutions, Inc. (EBS) Company Bio


Emergent BioSolutions is a biopharmaceutical company which develops, manufactures, and delivers a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. The company was founded in 1998 and is based in Gaithersburg, Maryland.

EBS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$89.97$67.98 -26%

We started the process of determining a valid price forecast for Emergent BioSolutions Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Emergent BioSolutions Inc ranked in the 38th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. In terms of the factors that were most noteworthy in this DCF analysis for EBS, they are:

  • Emergent BioSolutions Inc's effective tax rate, as measured by taxes paid relative to net income, is at 18 -- greater than 74.15% of US stocks with positive free cash flow.
  • Emergent BioSolutions Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at 7.68. This coverage rate is greater than that of 73.15% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 8. This value is greater than only 23.92% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-27%
1%-26%
2%-26%
3%-25%
4%-24%
5%-23%

Want more companies with a valuation profile/forecast similar to that of Emergent BioSolutions Inc? See ICLR, NVS, STE, BDX, and RSCF.


EBS Latest News Stream


Event/Time News Detail
Loading, please wait...

EBS Latest Social Stream


Loading social stream, please wait...

View Full EBS Social Stream

Latest EBS News From Around the Web

Below are the latest news stories about Emergent BioSolutions Inc that investors may wish to consider to help them evaluate EBS as an investment opportunity.

Insider Sells Emergent BioSolutions Stock

Shares of Emergent BioSolutions Inc (NYSE:EBS) fell by 3.5% from the previous closing price. Harsanyi Zsolt filed a Form 4 with the SEC on Tuesday, August …

Benzinga | August 18, 2020

Uma Sharma, PhD of MMS Holdings and Ron Perry of Emergent BioSolutions Join MichBio Board of Directors

ANN ARBOR, Mich.--(BUSINESS WIRE)-- #bioindustry--MichBio welcomes Uma Sharma, PhD Chief Scientific Officer at MMS Holdings and Ron Perry Vice President and General Manager at Emergent BioSolutions to the Board of Directors. Uma Sharma, PhD was appointed in mid-August to complete a term expiring in December 2021. As the CSO of MMS Holdings, she is a hands-on leader focused on guiding sponsors on clinical strategy and colleagues through an inclusive leadership model. Dr. Sharma has a personal philosophy of pay

Business Wire | August 18, 2020

FDA OKs shelf life extension for Emergent Bio's Narcan

The FDA has approved Emergent BioSolutions' (EBS) shelf life extension of NARCAN (naloxone HCl) Nasal Spray from 24 months to 36 months.Narcan Nasal Spray was the first intranasal form of naloxone approved for the emergency treatment of known or suspected opioid overdose....

Seeking Alpha | August 17, 2020

COVID-19 treatment: Biological E to manufacture substance needed in J&J's vaccine

J&J aims to produce more than 1 billion doses of its vaccine candidate, and has struck a similar deal with U.S.-based Emergent BioSolutions Inc to boost manufacturing

Business Today | August 13, 2020

The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX ) (announced introduction of AditxtScore for COVID-19 to be used in detecting antibodies against SARS-CoV-2 antigens) Axonics Modulation Technologies Inc (NASDAQ: AXNX ) Biocept Inc (NASDAQ: BIOC ) (announced an agreement with Aegea for a highly sensitive PCR-based assay designed by the latter for detecting the COVID-19 virus) DarioHealth Corp (NASDAQ: DRIO ) Denali Therapeutics Inc (NASDAQ: DNLI )( announced selection of candidate to enter Phase 3 study in Parkinson's disease) Editas Medicine Inc (NASDAQ: EDIT )(moved on M&A speculation) Emergent Biosolutions Inc (NYSE: EBS ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) ITAMAR MED LTD/S ADR (NASDA...

Benzinga | August 7, 2020

Read More 'EBS' Stories Here

EBS Price Returns

1-mo -15.03%
3-mo -19.12%
6-mo 13.17%
1-year 52.34%
3-year 123.81%
5-year 170.99%
YTD 66.77%
2019 -8.99%
2018 27.57%
2017 41.50%
2016 -17.92%
2015 46.93%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8496 seconds.